$BOT have issued a release confirming that initial prescriptions of Sofdra have been delivered via the patient experience program run in conjunction with IHhS.

ASX Announcement

Their Headlines

• Patient Experience Program underway with first prescriptions issued and Sofdra delivered to patients

• Inventory build and logistics infrastructure testing completed to support full commercial launch in Q1 2025

• Marketing and sales materials developed, tested and refined

• Sales force engaged and preparing for launch meeting in late January, followed by digital program expansion

My Assessment

Basically, this is a communication saying everything is going according to plan.

My view is that the first significant information will come after 1Q 2025, when we see data on the number of prescriptions in what will be a partial quarter after full launch, with hopefully some information on refill rates from early patients.

Still, this is good news, and good that management are keeping the market informed that everything is progressing as planned. Of particular note are 1) that supply chain is prepared and able to flex according to demand and 2) that insurer reimbursement is working as planned. These are both important elements of execution risk showing an initial "green light". Early days, of course, but nonetheless positive.

Disc: Held in RL and SM